Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. - Wikidata - thesis-toulmin - TriplyDB

Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.

Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.

http://www.wikidata.org/entity/Q48685934

about

Opportunities and challenges for successful use of bevacizumab in pediatrics.Advances in the management of paediatric high-grade glioma.Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.Pediatric low-grade gliomas: how modern biology reshapes the clinical field.Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.Immunotherapy in pediatric malignancies: current status and future perspectives The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma.Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.Targeted therapy in pediatric low-grade glioma.Necrotic ulcerated and bleeding striae distensae following bevacizumab in a palliative setting for gliobastomatosis cerebri Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis.Angiogenesis and angiogenic tyrosine kinase receptor expression in pediatric brain tumors.Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature.Treatment of childhood astrocytomas with irinotecan and cisplatin.18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.

P2860

Q30454883-9E9ABBAD-5457-4CFC-B1D9-80DAE61F95DF Q30870633-FA7FFAA2-17C9-4759-9515-28FBE875EF2C Q30908379-523DFFA5-8699-4B46-BE17-A8E8529466DB Q33847771-5EBCA9E8-C0AE-4A61-A1D4-F7DB2CFE0744 Q36261159-247F49BC-79BF-46F3-85CC-7D01B0C8E3CB Q36691818-05A55C64-E9D5-499B-9608-3E07DB3C543A Q36833480-187B9ECB-1B3F-4AAB-BFEC-21F1C4F996C4 Q37484213-8F996BCA-F4D6-4AA5-8174-93D16CFE85C0 Q37485279-47158CA9-61B0-4585-BE73-7E68A3A09CE9 Q38055317-9CAAF303-EAD3-4F9E-9A53-05C1D1EA0D64 Q38133407-90A90FE4-7366-40C5-9B58-A29898EC11B3 Q38194055-1406EAFC-B22E-4DE1-ACBF-B03624B89D9C Q41545867-03B2D1E9-2B6A-4AD8-AC4E-35FDA96B0ECB Q42420669-DC506477-F389-453F-8B0E-17045CF924D3 Q44661518-23E366BF-AB59-47AA-A279-4A2BBC5FFBE7 Q44819993-59052194-881F-46C0-AFA6-3CB30D98956D Q47911576-E0D7689B-307A-41CF-96D0-241CDD8F5425 Q48204130-D595C7DE-D706-4D19-BF0A-3C73A731CD45 Q52801683-2459908D-87A5-478D-BA0A-D4B9D1558581

P2860

Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.

http://www.wikidata.org/entity/Q48685934

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Bevacizumab and irinotecan in ...... toxicity and efficacy trends.

@en

Bevacizumab and irinotecan in ...... toxicity and efficacy trends.

@nl

type

label

Bevacizumab and irinotecan in ...... toxicity and efficacy trends.

@en

Bevacizumab and irinotecan in ...... toxicity and efficacy trends.

@nl

prefLabel

Bevacizumab and irinotecan in ...... toxicity and efficacy trends.

@en

Bevacizumab and irinotecan in ...... toxicity and efficacy trends.

@nl

P1433

Q48685934-208E4A9D-96CF-4F2E-A9BD-0EBAAB5F47BD

P1476

Q48685934-3A9CC4FE-F2F7-42CF-AE74-EB24F904C961

P2093

Q48685934-2C4E9548-A931-46F3-BBB1-96CEB9A564F6

Q48685934-6AA063E4-37EB-421A-A70F-AACD187ED57E

Q48685934-7C2049C9-4523-4551-A54E-F52F3758FC34

Q48685934-7F949E24-6F6B-45E7-99E5-C47C041223CC

Q48685934-84947BF2-98A8-41C2-BFEA-A8C85561D0AC

Q48685934-932CCFEC-2F87-4C39-97F8-4D47DC6714F8

Q48685934-9BBBF669-9739-4261-9425-DB9EBCAC670E

Q48685934-D3A2FC7B-A57E-4D91-979B-7B7318751347

Q48685934-E7E63E31-5D64-4F70-8D0E-B432F51DFE43

Q48685934-FAFF8D5C-6EAD-4BC1-A1AC-18C46434DBEC

P2860

Q48685934-00C01B81-825D-4840-840A-4CE176B0A261

Q48685934-295355D4-FCAA-4012-B22E-5BDB99F7B9E1

Q48685934-2E47494E-5DDD-40AA-99A2-BAF11903CB92

Q48685934-38A33532-12DF-4CCD-8F1E-3BA5FFFC06F4

Q48685934-47637B8F-6435-4E6E-A722-3AC4994147D9

Q48685934-60F6E9D8-F830-4EE1-A5EE-A43167912179

Q48685934-73F69391-FADB-4917-9390-D2CAE6EBE6EA

Q48685934-889BB9D2-3C60-400D-9D98-FC67BD6F2E04

Q48685934-A2761708-460E-4CD5-B19F-3061E658B897

Q48685934-B256948F-404A-4F92-B534-4176BC3D5095

P304

Q48685934-C7AB89ED-8668-4C64-875B-7399F8FD7D64

P31

Q48685934-B279B7ED-6D1F-42E9-8B96-58CBF27ADE12

P356

Q48685934-DB6386FA-371F-45EA-837E-8B6477489DE8

P433

Q48685934-934034D3-771E-4467-AA29-E57C2347C82C

P478

Q48685934-0EC23510-0172-4BC5-91A8-5EAA55A2BB92

P50

Q48685934-D7BD71F7-4EE3-4A98-8E21-9EB4F9EB61F9

P577

Q48685934-64601B4A-7E8F-44B2-8416-233C56B6D92C

P698

Q48685934-7D573828-75B6-49FA-AF51-89A2CF1EB886

P921

Q48685934-7C642176-91DC-4B47-98F0-B13374362DC9

P356

P1433

Pediatric Blood & Cancer

P1476

Bevacizumab and irinotecan in ...... toxicity and efficacy trends.

@en

P2093

Comité Pharmacologie of the SFCE

http://www.w3.org/2001/XMLSchema#string

Estelle Thebaud

http://www.w3.org/2001/XMLSchema#string

Isabelle Aerts

http://www.w3.org/2001/XMLSchema#string

Marie-Laure Couec

http://www.w3.org/2001/XMLSchema#string

Nadège Corradini

http://www.w3.org/2001/XMLSchema#string

Nicolas André

http://www.w3.org/2001/XMLSchema#string

Odile Minckes

http://www.w3.org/2001/XMLSchema#string

Perrine Marec Bérard

http://www.w3.org/2001/XMLSchema#string

Pierre Leblond

http://www.w3.org/2001/XMLSchema#string

Xavier Rialland

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

The biology of VEGF and its receptors

Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody.

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

Bevacizumab in recurrent high-grade pediatric gliomas

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

P304

34-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.24066

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Franck Bourdeaut

P577

2012-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22287258

http://www.w3.org/2001/XMLSchema#string

P921